BR9912902A - 1,8-naftiridin-4(1h)-onas substituìdas como inibidores de fosfodiesterase 4 - Google Patents
1,8-naftiridin-4(1h)-onas substituìdas como inibidores de fosfodiesterase 4Info
- Publication number
- BR9912902A BR9912902A BR9912902-7A BR9912902A BR9912902A BR 9912902 A BR9912902 A BR 9912902A BR 9912902 A BR9912902 A BR 9912902A BR 9912902 A BR9912902 A BR 9912902A
- Authority
- BR
- Brazil
- Prior art keywords
- phosphodiesterase
- inhibitors
- naphthyridin
- allergic
- disease
- Prior art date
Links
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title abstract 2
- NQUIRWXTTAMWIU-UHFFFAOYSA-N 1h-1,8-naphthyridin-4-one Chemical group C1=CC=C2C(O)=CC=NC2=N1 NQUIRWXTTAMWIU-UHFFFAOYSA-N 0.000 title 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 206010044248 Toxic shock syndrome Diseases 0.000 abstract 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000006583 body weight regulation Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000004260 weight control Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Patente de Invenção: <B>"1,8-NAFTIRIDIN-4(1H)-ONAS SUBSTITUìDAS COMO INIBIDORES DE FOSFODIESTERASE 4"<D>. Um composto de fórmula ou um seu sal farmaceuticamente aceitável, em que R¹, R² e R³ são como defenido acima, úteis no tratamento de distúrbios respiratórios, alérgicos, reumatóides, regulação do peso do corpo, inflamatório e do sistema nervoso central tais como asma, doenças pulmonares obstrutivas crónicas, síndrome de doenças respiratórias de adultos, choque tóxico, fibroses, hipersensibilidade pulmonar, rinites alérgicas, dermatites atópicas, psoríase, controle de peso, artrites reumatóides, caquexia, doença de Crohn, colite ulcerosa, condições artríticas e outras doenças inflamatórias, depressão, demência de multienfarte e AIDS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9617698P | 1998-08-11 | 1998-08-11 | |
| PCT/IB1999/001390 WO2000009504A1 (en) | 1998-08-11 | 1999-08-05 | Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9912902A true BR9912902A (pt) | 2001-05-08 |
Family
ID=22256080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9912902-7A BR9912902A (pt) | 1998-08-11 | 1999-08-05 | 1,8-naftiridin-4(1h)-onas substituìdas como inibidores de fosfodiesterase 4 |
Country Status (44)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815951B2 (en) | 1996-08-13 | 2014-08-26 | The Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of inflammation |
| EP1343528A2 (en) * | 2000-11-02 | 2003-09-17 | Research Foundation of City University of New York | Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| JO2311B1 (en) * | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| ATE409187T1 (de) * | 2002-03-15 | 2008-10-15 | Merck & Co Inc | N-(substituierte benzyl)-8-hydroxy-1,6- naphthyridin-7- carbonsäureamide als hiv- integrase-hemmer |
| KR100454750B1 (ko) * | 2002-06-20 | 2004-11-03 | 삼성에스디아이 주식회사 | 유기 전계 발광 소자용 청색 발광 화합물 및 이를 사용한유기 전계 발광 소자 |
| WO2004047817A1 (en) * | 2002-11-27 | 2004-06-10 | Altana Pharma Ag | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia |
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE10349497A1 (de) * | 2003-10-23 | 2005-05-25 | Bayer Cropscience Ag | N-substituierte Pyrazolylcarboxanilide |
| CA2552540A1 (en) * | 2004-01-17 | 2005-07-28 | Boehringer Ingelheim International Gmbh | Use of substituted pteridines for the treatment of diseases of the respiratory tract |
| DE102004002557A1 (de) * | 2004-01-17 | 2005-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen |
| DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004058337A1 (de) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| CA2617589A1 (en) * | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Dihydropteridinones in the treatment of respiratory diseases |
| US7439358B2 (en) * | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| WO2009019205A1 (en) * | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| KR102083154B1 (ko) * | 2012-08-08 | 2020-03-02 | 메르크 파텐트 게엠베하 | （아자―）이소퀴놀리논 유도체 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| EP3024464A1 (en) | 2013-07-26 | 2016-06-01 | Boehringer Ingelheim International GmbH | Treatment of myelodysplastic syndrome |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU165405B (pt) * | 1972-06-29 | 1974-08-28 | ||
| US3856800A (en) * | 1973-02-26 | 1974-12-24 | Sterling Drug Inc | Process of preparing 1,4-dihydro-4-oxo-7-q-3-unsubstituted-1,8-naphthyridines from cyclic alkylidenyl n-(6-q-2-pyridyl) aminomethylenemalonates |
| US3882132A (en) * | 1973-03-08 | 1975-05-06 | Sterling Drug Inc | Preparation of 1-alkyl-1,4-dihydro-7-substituted-4-oxo-1,8-naphthyridine-3-carboxylic acids via the 3-aminomethyl analogs |
| WO1996006843A1 (en) * | 1994-08-29 | 1996-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Novel naphthyridine derivative and medicinal composition thereof |
| JP4323574B2 (ja) * | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | 抗腫瘍剤 |
-
1999
- 1999-08-05 ID IDW20010315A patent/ID27843A/id unknown
- 1999-08-05 OA OA1200100032A patent/OA11591A/en unknown
- 1999-08-05 DK DK99933078T patent/DK1104420T3/da active
- 1999-08-05 DE DE69904602T patent/DE69904602T2/de not_active Expired - Fee Related
- 1999-08-05 BR BR9912902-7A patent/BR9912902A/pt not_active Application Discontinuation
- 1999-08-05 CN CN99809505A patent/CN1312810A/zh active Pending
- 1999-08-05 CZ CZ2001485A patent/CZ2001485A3/cs unknown
- 1999-08-05 ES ES99933078T patent/ES2188194T3/es not_active Expired - Lifetime
- 1999-08-05 EE EEP200100085A patent/EE200100085A/xx unknown
- 1999-08-05 PT PT99933078T patent/PT1104420E/pt unknown
- 1999-08-05 AU AU49249/99A patent/AU4924999A/en not_active Abandoned
- 1999-08-05 JP JP2000564956A patent/JP2002522541A/ja active Pending
- 1999-08-05 NZ NZ509297A patent/NZ509297A/en not_active Application Discontinuation
- 1999-08-05 PL PL99346005A patent/PL346005A1/xx not_active Application Discontinuation
- 1999-08-05 KR KR1020017001718A patent/KR20010072368A/ko not_active Ceased
- 1999-08-05 TR TR2001/00433T patent/TR200100433T2/xx unknown
- 1999-08-05 CA CA002340180A patent/CA2340180A1/en not_active Abandoned
- 1999-08-05 HR HR20010107A patent/HRP20010107A2/hr not_active Application Discontinuation
- 1999-08-05 HU HU0103466A patent/HUP0103466A3/hu unknown
- 1999-08-05 EA EA200100124A patent/EA200100124A1/ru unknown
- 1999-08-05 AT AT99933078T patent/ATE229955T1/de not_active IP Right Cessation
- 1999-08-05 WO PCT/IB1999/001390 patent/WO2000009504A1/en not_active Ceased
- 1999-08-05 HK HK02100400.2A patent/HK1038917A1/zh unknown
- 1999-08-05 IL IL14086899A patent/IL140868A0/xx unknown
- 1999-08-05 EP EP99933078A patent/EP1104420B1/en not_active Expired - Lifetime
- 1999-08-05 AP APAP/P/2001/002068A patent/AP2001002068A0/en unknown
- 1999-08-05 GE GEAP19995743A patent/GEP20033029B/en unknown
- 1999-08-05 SK SK182-2001A patent/SK1822001A3/sk unknown
- 1999-08-06 TW TW088113482A patent/TW542835B/zh active
- 1999-08-09 HN HN1999000130A patent/HN1999000130A/es unknown
- 1999-08-09 GT GT199900128A patent/GT199900128A/es unknown
- 1999-08-09 PE PE1999000802A patent/PE20000950A1/es not_active Application Discontinuation
- 1999-08-10 TN TNTNSN99155A patent/TNSN99155A1/fr unknown
- 1999-08-10 AR ARP990103992A patent/AR015557A1/es not_active Application Discontinuation
- 1999-08-10 MA MA25723A patent/MA26669A1/fr unknown
- 1999-08-10 SV SV1999000120A patent/SV1999000120A/es not_active Application Discontinuation
- 1999-08-10 PA PA19998480001A patent/PA8480001A1/es unknown
- 1999-08-10 DZ DZ990166A patent/DZ2866A1/xx active
- 1999-08-11 US US09/372,735 patent/US6174895B1/en not_active Expired - Fee Related
- 1999-08-11 CO CO99051075A patent/CO5130004A1/es unknown
-
2001
- 2001-01-16 IS IS5815A patent/IS5815A/is unknown
- 2001-02-07 ZA ZA200101040A patent/ZA200101040B/en unknown
- 2001-02-09 NO NO20010684A patent/NO20010684L/no not_active Application Discontinuation
- 2001-03-09 BG BG105321A patent/BG105321A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9912902A (pt) | 1,8-naftiridin-4(1h)-onas substituìdas como inibidores de fosfodiesterase 4 | |
| EA199900787A1 (ru) | Производные никотинамида | |
| MXPA02005465A (es) | Derivados de triazaspiro(5.5)undecano y composiciones farmaceuticas que los comprenden, como un ingrediente activo. | |
| PT1378510E (pt) | Derivados de triazaespiro [5.5] undecano e farmacos que os contem como componentes activos | |
| EP0730588A1 (en) | ISOXAZOLINE COMPOUNDS AS AN ANTI-FLAMMING AGENT | |
| DE69426830D1 (en) | Substituierte indole als phosphodiesterase typ iv inhibitoren | |
| DE69615214D1 (de) | Substituierte heteroaromatische derivate | |
| TNSN08131A1 (en) | Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist | |
| MXPA04004019A (es) | Derivados de pirimido?4,5-b?indol. | |
| WO2006034317A3 (en) | Chemical compounds | |
| NO971811L (no) | Bicykliske tetrahydropyrazolopyridiner og deres anvendelse som legemidler | |
| NO20073436L (no) | Nye heterosykliske forbindelser nyttige for behandling av inflammatoriske og allergiske forstyrrelser | |
| ECSP993095A (es) | 1-aril-3- arilmetil -8 -naftiridin -4 (1h)-(onas) | |
| ECSP982468A (es) | Derivados de nicotinamida | |
| BRPI0516373A (pt) | derivados de pirido(3,2-d)pirimidinas e uso dos mesmos | |
| TH43442A (th) | อนุพันธ์นิโคตินเอไมด์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DA INT.CL: A61K 31/4375, C07D 471/04, A61K 31/44, A61P 11/06, A61P 17/06, A61P 19/02, A61P 29/00, A61P 37/00, A61P 37/08, A61P 43/00 Ipc: C07D 471/04 (2009.01), A61K 31/44 (2009.01) |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM ARTIGOS 8O, 10 ( VIII ), 11,13, 24 E 25 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |